Details for Patent: 11,045,470

Which drugs does patent 11,045,470 protect, and when does it expire?

Patent 11,045,470 protects ORIAHNN (COPACKAGED) and is included in one NDA.

This patent has eight patent family members in five countries.

Summary for Patent: 11,045,470

Patent landscape, scope, and claims:

Title:	Methods of treating heavy menstrual bleeding
Abstract:	The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-ben- zyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino- )-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Inventor(s):	Chwalisz; Kristof (Mundelein, IL), Williams; Laura A. (Gurnee, IL), Jain; Rita I. (Evanston, IL), North; Janine D. (Chicago, IL), Ng; Juki Wing-Keung (Highland Park, IL)
Assignee:	ABBVIE INC. (North Chicago, IL)
Application Number:	16/355,359
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 11,045,470

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	ORIAHNN (COPACKAGED)	elagolix sodium,estradiol,norethindrone acetate; elagolix sodium	CAPSULE;ORAL	213388-001	May 29, 2020		RX	Yes	Yes	11,045,470					MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)

International Family Members for US Patent 11,045,470

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2906894
European Patent Office	2968566
European Patent Office	3384930
European Patent Office	4223298